Completed PHASE3 INTERVENTIONAL 4-arm NCT04937387

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

A Phase III, 12 Week, Randomized, Double-blind, 4 Arm Parallel Group Bridging Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI Once-daily Via a Dry Powder Inhaler With Dual Combination of FF/VI, Administered in Chinese Participants With Inadequately Controlled Asthma

Sponsor: GlaxoSmithKline

Conditions Asthma

Interventions ELLIPTA FF/UMEC/VI FF/VI

Updated 15 times since 2021 Last updated: Jul 24, 2025 Started: Jul 29, 2021 Primary completion: Aug 5, 2024 Completion: Aug 5, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04937387, this PHASE3 trial focuses on Asthma and remains completed. Sponsored by GlaxoSmithKline, it has been updated 15 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

15 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Feb 2025 — Sep 2025 [monthly]

Completed PHASE3

Status: Unknown → Completed
Nov 2024 — Feb 2025 [monthly]

Unknown PHASE3

Status: Recruiting → Unknown
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3

▶ Show 10 earlier versions

Nov 2022 — Jul 2024 [monthly]

Recruiting PHASE3
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE3
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE3
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE3
May 2022 — Jun 2022 [monthly]

Recruiting PHASE3
Mar 2022 — May 2022 [monthly]

Recruiting PHASE3
Jan 2022 — Mar 2022 [monthly]

Recruiting PHASE3
Dec 2021 — Jan 2022 [monthly]

Recruiting PHASE3
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE3
Sep 2021 — Nov 2021 [monthly]

Recruiting PHASE3

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Dongguan, China , Fuzhou, China , Guangzhou, China , Guilin, China , Hangzhou, China and 34 more locations